Clinical outcome of breast and ovarian cancer patients treated after high-dose chemotherapy and autologous stem cell rescue with theratope (STn-KLH) cancer vaccine theratope (STn-KLH) cancer vaccine following autologous transplant

ACS Symposium Series

Volumn 990, Issue , 2008, Pages 197-215

  Holmberg, Leona A ^a,b   Guthrie, Katherine A ^a,c   Sandmaier, Brenda M ^a,b  

^a Clinical Research Division   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOTHERAPY; DISEASES; IMMUNE SYSTEM; PATIENT MONITORING; STEM CELLS; TUMORS; VACCINES;

AUTOLOGOUS TRANSPLANTS; CELLULAR RESPONSE; CLINICAL OUTCOME; HIGH-DOSE CHEMOTHERAPIES; IMMUNE RESPONSE; LONG-TERM OUTCOME; OVARIAN CANCER CELLS; PERIPHERAL BLOOD STEM CELLS;

PATIENT TREATMENT;

EID: 84905595579     PISSN: 00976156     EISSN: 19475918     Source Type: Book Series    
DOI: 10.1021/bk-2008-0990.ch009     Document Type: Conference Paper

References (26)

1. Kroger N.; Frick M.; Glisz O. et al. Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancer. J Clin Oncol 2006, 24, 3919-3926.
2. Hanrahan E.; Broglio K.; Frye D. et al. Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years. Cancer 2006, 106, 2327- 2336.
3. Bensinger W. I.; Schiffman K. S.; Holmberg L. et al. High dose busulfan, melphalan, thiotepa and peripheral blood stem cell infusion for the treatment of metastatic breast cancer. Bone Marrow Transplant 1997, 19, 1183-1189.
4. Gutierrez-Delgado F.; Holmberg L. A.; Hooper H. et al. High-dose busulfan, melphalan and thiotepa as consolidation for non-inflammatory high-risk breast cancer. Bone Marrow Transplant 2000, 26, 51-59.
5. Stiff P. J.; Bayer R.; Kreger C. et al. High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients. J Clin Oncol 1997, 15, 1309-1317.
6. Holmberg L. A.; Demirer T.; Rowley S. et al. High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancer. Bone Marrow Transplant 1998, 22, 651-659.
7. Holmberg L. A.; Kikuchi K.; Gooley T. et al. Gastrointestinal graft versus host disease in recipients of autologous hematopoietic stem cells: incidence, risk factors and outcome. Biol of Blood Marrow Transpl 2006, 12, 226-234.
8. Adams K. M.; Holmberg L. A.; Leisenrig W. et al. Risk factors for syngeneic graft-versus-host disease after adult hematopoietic cell transplantation. Blood 2004, 104, 1894-1897.
9. Thor A.; Ohuchi N.; Szpak C. A. et al. Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. Cancer Res 1986, 46, 3118-3124.
10. Reddish M. A.; Jackson L.; Kogantry R. R. et al. Specificities of anti-sialyl- Tn and anti-Tn monoclonal antibodies generated using novel clustered synthetic glycopeptides epitopes. Glycoconj J 1997, 14, 549-560.
11. Girling A.; Bartkova J.; Burchell J. et al. A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas. Int J Cancer 1989, 43, 1072-1076.
12. Kinney A. Y.; Sahin A.; Vernon S. W. et al. The prognostic significance of sialyl-Tn antigen in women treated with breast carcinoma treated with adjuvant chemotherapy. Cancer 1997, 80, 2240-2249.
13. Kobayashi H.; Terao T.; Kawashima Y. et al. Serum sialyl n as an independent predictor of poor prognosis in patients with epithelial ovarian cancer. J Clin Oncol 1992, 10, 95-101.
14. Fung P. Y. S.; Madej M.; Koganty R. R.; Longenecker B. M. Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate. Cancer Res 1990, 50, 4308- 4314.
15. Singhal A.; Fohn M.; Hakomari S. I. Induction of alpha N- acetylgalactosamine-O-serine/threonine (Tn) antigen-mediated cellular immune response for active immunotherapy in mice. Cancer Res 1991, 51, 406-411.
16. MacLean G. D.; Reddish M. A.; Kogarty R. R. et al. Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox Tm adjuvant. Cancer Immunol Immunother 1993, 36, 215-222.
17. Sandmaier B. M.; Oparin D. V.; Holmberg L. A. et al. Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue and immunization with Theratope STn -KLH cancer vaccine. J Immunotherapy 1999, 22, 54- 66.
18. Holmberg L. A.; Oparin D. V.; Gooey T.; Sandmaier B. The role of cancer vaccines following autologous stem cell rescue in breast and ovarian cancer patients: experience with the STn-KLH vaccine (Theratope). Clinical Breast Cancer (Supple) 2003, 144-150.
19. Holmberg L. A.; Oparin D. V.; Gooley T. et al. Clinical outcome of breast and ovarian cancer patients treated with high dose chemotherapy, autologous stem cell rescue and Theratope vaccine STn-KLH cancer vaccine. Bone Marrow Transpl 2000, 25, 1233-1241.
20. Nieto Y.; Shpall E. J.; McNiece I. K. et al. Prognostic analysis of early lymphocyte recovery in patients with advanced breast cancer receiving high- dose chemotherapy with an autologous hematopoietic progenitor cell transplant. Clinic Cancer Res 2004, 10, 5076-86.
21. Chan C. Y.; Molrine D. C.; Antin J. H. et al. Antibody responses to tetanus toxoid and Haemophilus influenza type b conjugate vaccine following autologous peripheral blood stem cell transplantation (PBSCT). Bone Marrow Transplant 1997, 20, 33-38.
22. Rosillo M. C.; Ortuno F.; Moraleda J. M. et al. Immune recovery after autologous or rh-G-CSF primed PBSC transplantation. Euro J Haematol 1996, 56, 301-307.
23. Steingrimsdottir H.; Gruber A.; Bjorkholm M. et al. Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications. Haematologica 2000, 85, 832-838.
24. Hernandez M. D.; delCanizo M. C.; Gonzalez M. et al. Immune reconstitution after autologous progenitor hemopoietic cell transplantation. A study comparing autologous bone marrow and autologous peripheral blood transplantation. Medicina Clinica 1998, 110, 768-773.
25. Avigan D.; Wu J.; Joyce R. et al. Immune reconstitution following high- dose chemotherapy with stem cell rescue in patients with advanced breast cancer. Bone Marrow Transplant 2000, 26, 169-176.
26. MacLean G. D.; Reddish M. A.; Longenecker B. M. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J Immunotherapy 1996, 19, 9-68.